Researchers in Boston are set to co-lead a long-term study on the aging brain and factors that make individuals more vulnerable to neural injury and cognitive decline.
Either the stakeholders issuing the warnings overstated the risk of widespread closings—or COVID-era emergency funds succeeded in heading off a calamity of national proportions. Either way, patient access has taken a hit here and there.
A special report is raising new concerns about a hospital’s lackluster response to a radiologist's concerns of abuse happening in the organization's NICU.
Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.
Some of today’s most popular products promise better immune, adaptogenic, anti-inflammatory, gut, skin or joint health—or combinations of two or more of the above.
Tennessee-based Xsolis said the incident occurred in January, and the sensitive data was from its clients. The company provides AI-powered case management software to hospitals and health insurers.
As the Medicare drug price negotiation program enters its fourth year next year, regulators are looking to put a set of guidelines in place that make it clear how medications are selected for inclusion and what the deliberation process will look like for biopharma companies.
Coming in at just 0.04 mmol gadolinium per kilogram body weight, gadoquatrane has 60% less gadolinium than the lowest dose GBCA currently on the market.
Researchers in Boston are set to co-lead a long-term study on the aging brain and factors that make individuals more vulnerable to neural injury and cognitive decline.
Either the stakeholders issuing the warnings overstated the risk of widespread closings—or COVID-era emergency funds succeeded in heading off a calamity of national proportions. Either way, patient access has taken a hit here and there.
